Literature DB >> 19388687

Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.

Yunden Jinsmaa1, Virginia R Florang, Jennifer N Rees, David G Anderson, Stefan Strack, Jonathan A Doorn.   

Abstract

Dopamine (DA) has been implicated as an endogenous neurotoxin to explain the selective neurodegeneration as observed for Parkinson's disease (PD). In addition, oxidative stress and lipid peroxidation are hypothesized culprits in PD pathogenesis. DA undergoes catabolism by monoamine oxidase (MAO) to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is further oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) via aldehyde dehydrogenase (ALDH). As a minor and compensatory metabolic pathway, DOPAL can be reduced to 3,4-dihydroxyphenylethanol (DOPET) via cytosolic aldehyde or aldose reductase (AR). Previous studies have found DOPAL to be significantly more toxic to DA cells than DA and that the major lipid peroxidation products, that is, 4-hydroxynonenal (4HNE) and malondialdehyde (MDA), potently inhibit DOPAL oxidation via ALDH. The hypothesis of this work is that lipid peroxidation products inhibit DOPAL oxidation, yielding aberrant levels of the toxic aldehyde intermediate. To test this hypothesis, nerve growth factor-differentiated PC6-3 cells were used as a model for DA neurons. Cell viability in the presence of 4HNE and MDA (2-100 microM) was measured by MTT assay, and it was found that only 100 microM 4HNE exhibited significant cytotoxicity. Treatment of cells with varying concentrations of 4HNE and MDA resulted in reduced DOPAC production and significant elevation of DOPAL levels, suggesting inhibition of ALDH. In cells treated with 4HNE that exhibited elevated DOPAL, there was a significant increase in DOPET. However, elevated DOPET was not observed for the cells treated with MDA, suggesting MDA to be an inhibitor of AR. Using isolated cytosolic AR, it was found that MDA but not 4HNE inhibited reductase activity toward DOPAL, surprisingly. These data demonstrate that the oxidative stress products 4HNE and MDA inhibit the aldehyde biotransformation step of DA catabolism yielding elevated levels of the endogenous neurotoxin DOPAL, which may link oxidative stress to selective neurodegeneration as seen in PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19388687      PMCID: PMC2696154          DOI: 10.1021/tx800405v

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  43 in total

1.  Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.

Authors:  B S Kristal; A D Conway; A M Brown; J C Jain; P A Ulluci; S W Li; W J Burke
Journal:  Free Radic Biol Med       Date:  2001-04-15       Impact factor: 7.376

Review 2.  Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies.

Authors:  T J Shafer; W D Atchison
Journal:  Neurotoxicology       Date:  1991       Impact factor: 4.294

3.  Aldehyde reductase gene expression by lipid peroxidation end products, MDA and HNE.

Authors:  Y H Koh; Y S Park; M Takahashi; K Suzuki; N Taniguchi
Journal:  Free Radic Res       Date:  2000-12

4.  Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells.

Authors:  M Kitazawa; V Anantharam; A G Kanthasamy
Journal:  Free Radic Biol Med       Date:  2001-12-01       Impact factor: 7.376

5.  Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.

Authors:  I Lamensdorf; G Eisenhofer; J Harvey-White; Y Hayakawa; K Kirk; I J Kopin
Journal:  J Neurosci Res       Date:  2000-05-15       Impact factor: 4.164

Review 6.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

7.  The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene.

Authors:  M E Burczynski; G R Sridhar; N T Palackal; T M Penning
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

8.  Kinetic and structural characterization of the glutathione-binding site of aldose reductase.

Authors:  B L Dixit; G K Balendiran; S J Watowich; S Srivastava; K V Ramana; J M Petrash; A Bhatnagar; S K Srivastava
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

9.  3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.

Authors:  William J Burke; Shu Wen Li; Evelyn A Williams; Randal Nonneman; Daniel S Zahm
Journal:  Brain Res       Date:  2003-11-07       Impact factor: 3.252

Review 10.  3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.

Authors:  W J Burke
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2003-04
View more
  44 in total

1.  Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

Authors:  Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2011-04-14       Impact factor: 4.294

2.  Time course of DNA adduct formation in peripheral blood granulocytes and lymphocytes after drinking alcohol.

Authors:  Silvia Balbo; Lei Meng; Robin L Bliss; Joni A Jensen; Dorothy K Hatsukami; Stephen S Hecht
Journal:  Mutagenesis       Date:  2012-03-09       Impact factor: 3.000

Review 3.  Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Authors:  David S Goldstein
Journal:  Cell Mol Neurobiol       Date:  2012-07       Impact factor: 5.046

4.  Cellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cells.

Authors:  Erin M G Allen; Virginia R Florang; Laurie L Davenport; Yunden Jinsmaa; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2013-06-27       Impact factor: 3.739

5.  Mentha piperita as a pivotal neuro-protective agent against gamma irradiation induced DNA fragmentation and apoptosis : Mentha extract as a neuroprotective against gamma irradiation.

Authors:  Hanaa A Hassan; Hani S Hafez; Mona S Goda
Journal:  Cytotechnology       Date:  2012-09-21       Impact factor: 2.058

Review 6.  Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Authors:  D S Goldstein
Journal:  Endocr Regul       Date:  2011-04

Review 7.  The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.

Authors:  Lena F Burbulla; Dimitri Krainc
Journal:  Neurobiol Dis       Date:  2019-07-25       Impact factor: 5.996

8.  Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.

Authors:  Lydia M M Vermeer; Virginia R Florang; Jonathan A Doorn
Journal:  Brain Res       Date:  2012-07-31       Impact factor: 3.252

9.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

Review 10.  Nitrative and oxidative stress in toxicology and disease.

Authors:  Ruth A Roberts; Debra L Laskin; Charles V Smith; Fredika M Robertson; Erin M G Allen; Jonathan A Doorn; William Slikker
Journal:  Toxicol Sci       Date:  2009-08-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.